AS01E佐剂呼吸道合胞病毒预融合F蛋白疫苗(RSVPreF3 OA)在老年人中三个呼吸道合胞病毒流行季的效力、安全性和免疫原性(AReSVi-006):一项多中心、随机、观察者盲法、安慰剂对照3期试验
AReSVi-006研究在17个国家275个中心纳入60岁及以上老年人,随机1:1接种RSVPreF3 OA或安慰剂,第二季前疫苗组再随机1:1接受第二剂或安慰剂。三个流行季单剂疫苗对RSV-LRTD累积效力62.9%(97.5%CI 46.7-74.8),对RSV A相关LRTD效力69.8%(42.2-85.7),对RSV B相关LRTD效力58.6%(35.9-74.1)。效力随时间下降,首剂后1年再接种的效力与单剂在同一范围。安全性可接受,严重不良事件发生率低。
要点
- 60岁及以上老年人单剂RSVPreF3 OA疫苗,三个RSV流行季对RSV-LRTD累积效力62.9%(97.5%CI 46.7-74.8)。
- 对RSV A相关LRTD效力69.8%(42.2-85.7),对RSV B相关LRTD效力58.6%(35.9-74.1)。
- 效力在60-69岁、70-79岁、衰弱前期(步速0.4-0.99 m/s)及有增加RSV-LRTD风险基础疾病者中均观察到。
- 效力随时间下降;首剂后1年再接种的效力与单剂在同一范围。
- 严重不良事件被认为与试验干预相关者:单剂组8例(<1%)、再接种组12例(<1%)、安慰剂组12例(<1%)。
适用人群与场景
- 60岁及以上老年人,来自非洲、亚洲、大洋洲、欧洲和北美17个国家的275个中心(全科诊所和临床研究机构)。
- 效力分析纳入12 468例RSVPreF3 OA受者和12 498例安慰剂受者。
处置流程与药物剂量
- 第一季前随机1:1接种RSVPreF3 OA或安慰剂;疫苗受者在第二季前再随机1:1接受第二剂RSVPreF3 OA(再接种组)或安慰剂(单剂组);第一季前安慰剂受者在第二季前接受安慰剂(安慰剂组)。
研究设计与关键结果
- 多中心、随机、观察者盲法、安慰剂对照3期试验;2021年5月25日至2022年1月31日入组。
- 单剂RSVPreF3 OA三个流行季对RSV-LRTD累积效力62.9%(97.5%CI 46.7-74.8),对RSV A相关LRTD效力69.8%(42.2-85.7),对RSV B相关LRTD效力58.6%(35.9-74.1);首剂后第15天起中位随访30.6个月(IQR 26.2-32.0)。
- 效力在60-69岁、70-79岁、衰弱前期(步速0.4-0.99 m/s)及有增加RSV-LRTD风险基础疾病者中均观察到;效力随时间下降。
- 首剂后1年再接种的效力与单剂在同一范围。
- 第一剂至试验结束,研究者认为与试验干预相关的严重不良事件:单剂组8例(<1%)、再接种组12例(<1%)、安慰剂组12例(<1%)。
- 研究者评估与试验干预相关的死亡5例:疫苗组3例(心肺衰竭、心脏骤停、左心室衰竭),安慰剂组2例(死因不明、肺栓塞)。
证据类型、等级与局限
- 3期随机、观察者盲法、安慰剂对照试验;确证性次要目标成功标准为效力估计值双侧CI下限>20%(RSV-LRTD)和>0%(按RSV亚型的RSV-LRTD)。
- 局限:原文未报告局限性;原文指出需进一步研究以确定最佳再接种策略。
对床旁实践的改变
- 单剂RSVPreF3 OA疫苗在60岁及以上老年人中三个RSV流行季对RSV-LRTD有保护效力,但效力随时间下降;作者认为需进一步研究以确定最佳再接种策略。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Duration of protection after respiratory syncytial virus (RSV) vaccination is unknown. This study aimed to evaluate efficacy and safety over three RSV seasons of the AS01E-adjuvanted RSV prefusion F protein-based vaccine (RSVPreF3 OA) against RSV-related lower respiratory tract disease (RSV-LRTD) in older adults.
METHODS: In this randomised, observer-blind, placebo-controlled, phase 3 trial (AReSVi-006), participants aged 60 years or older in 275 centres (ie, GP practices and clinical research sites) across 17 countries in Africa, Asia, Oceania, Europe, and North America were randomly assigned (1:1) to receive RSVPreF3 OA or placebo before RSV season one. RSVPreF3 OA recipients were re-randomly assigned (1:1) before RSV season two to receive a second RSVPreF3 OA dose (RSV revaccination group) or placebo (RSV single-dose group). Recipients of placebo before RSV season one also received placebo before season two (placebo group). The primary objective (efficacy against first occurrence of RSV-LRTD over one RSV season) was reported previously. Confirmatory secondary objectives were to demonstrate efficacy over three RSV seasons of a single RSVPreF3 OA dose and of a first dose followed by revaccination 1 year later, against RSV-LRTD, overall and by RSV subtype (success criteria: lower limits of two-sided CIs around efficacy estimates >20% [RSV-LRTD] and >0% [RSV-LRTD by RSV subtype]). This study is registered with ClinicalTrials.gov, NCT04886596, and is complete.
FINDINGS: Participants were enrolled between May 25, 2021, and Jan 31, 2022. Efficacy analyses included 12 468 RSVPreF3 OA recipients and 12 498 placebo recipients. Cumulative efficacy over three seasons of one RSVPreF3 OA dose was 62·9% (97·5% CI 46·7-74·8) against RSV-LRTD, 69·8% (42·2-85·7) against RSV A-related LRTD, and 58·6% (35·9-74·1) against RSV B-related LRTD (median follow-up from day 15 post-dose one 30·6 months [IQR 26·2-32·0]). Efficacy was observed over three seasons among participants aged 60-69 years, participants aged 70-79 years, pre-frail participants (ie, those with a walking speed of 0·4-0·99 m/s in a gait speed test), and participants with pre-existing conditions that increase the RSV-LRTD risk. Efficacy against RSV-LRTD decreased over time. A first RSVPreF3 OA dose followed by revaccination 1 year later had an efficacy that was within the same range as that of one dose. RSVPreF3 OA showed a clinically acceptable safety profile. Between dose one and trial end, eight (<1%) participants in the RSV single-dose group, 12 (<1%) in the RSV revaccination group, and 12 (<1%) in the placebo group had a serious adverse event considered to be related to the trial intervention by the investigator. Five deaths were assessed as related to the trial intervention by the investigator: three in the vaccine groups (cardiopulmonary failure, cardiac arrest, and left ventricular failure) and two in the placebo group (death of unknown cause and pulmonary embolism).
INTERPRETATION: A single RSVPreF3 OA dose was efficacious against RSV-LRTD over three RSV seasons in people aged 60 years or older, despite a decrease in efficacy over time. Further research is needed to establish the optimal revaccination strategy. These results support the favourable benefit-risk profile of RSVPreF3 OA to help protect against RSV-LRTD for at least three RSV seasons.
参考来源
- Ison MG, Papi A, Athan E, et al. Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med. 2025. PMID: 40245915. doi:10.1016/S2213-2600(25)00048-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。